Tata Power in spotlight after Q4 results

On a consolidated basis, Tata Power reported a net profit of Rs 1477.50 crore in Q4 March 2018 compared with net loss of Rs 226.93 crore in Q4 March 2017. Net sales rose 12.70% to Rs 7895.23 crore in Q4 March 2018 over Q4 March 2017. The result was announced after market hours yesterday, 2 May 2018.

InterGlobe Aviation's net profit fell 73.3% to Rs 117.64 crore on 19.6% increase in net sales to Rs 5799.11 crore in Q4 March 2018 over Q4 March 2017. The result was announced after market hours yesterday, 2 May 2018.

Siemens' net profit rose 18% to Rs 219.70 crore on 10.6% increase in net sales to Rs 3163.10 crore in Q2 March 2018 over Q2 March 2017. The result was announced after market hours yesterday, 2 May 2018.

Adani Ports & Special Economic Zone and Vedanta will declare their Q4 March 2018 results today, 3 May 2018.

Biocon will be watched. The US Food and Drug Administration (USFDA) has completed a pre-approval inspection of the company's sterile drug product manufacturing facility in Bangalore this week and issued a Form 483 with 7 observations. The observations are largely procedural and aimed at continuous improvement. The company will respond to the FDA with a corrective and preventive action plan in a timely manner.

Further, Biocon has also received the preliminary report from the European Regulator post inspection of the company's sterile drug product facility in Bangalore in March 2018. The report lists 6 major observations with no observation classified as critical. Biocon will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period. The announcement was made after market hours yesterday, 2 May 2018.

Cadila Healthcare announced that it received the final approval from the US Food and Drug Administration (USFDA) to market Bumetanide tablets USP in the strengths of 0.5 mg, 1 mg, and 2 mg. It is used to treat edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. It will be manufactured at the group's manufacturing facility at Baddi. The group now has more than 185 approvals and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-2004. The announcement was made after market hours yesterday, 2 May 2018.

Power Grid Corporation of India said that its board approved three investments worth Rs 461.63 crore. The announcement was made after market hours yesterday, 2 May 2018.

Adani Transmission announced the appointment of Anil Sardana as managing director and chief executive officer of the company with effect from 1 May 2018. The announcement was made after market hours yesterday, 2 May 2018.

Powered by Capital Market - Live News